• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Prognostic value of blood GRHL2 in patients with non-small-cell lung cancer after radiotherapy and chemotherapy.放疗和化疗后血液 GRHL2 对非小细胞肺癌患者的预后价值。
Biomark Med. 2024;18(13-14):611-617. doi: 10.1080/17520363.2024.2366161. Epub 2024 Jul 29.
2
Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.循环 miR-125b 是一种新型非小细胞肺癌筛查生物标志物，可预测不良预后。
J Cancer Res Clin Oncol. 2012 Dec;138(12):2045-50. doi: 10.1007/s00432-012-1285-0. Epub 2012 Jul 18.
3
Serum extracellular vesicle microRNAs as potential biomarkers to predict pembrolizumab response and prognosis in metastatic non-small cell lung cancer patients.血清细胞外囊泡微小RNA作为预测转移性非小细胞肺癌患者帕博利珠单抗反应和预后的潜在生物标志物。
Front Immunol. 2025 Jun 4;16:1540906. doi: 10.3389/fimmu.2025.1540906. eCollection 2025.
4
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.免疫检查点抑制剂联合铂类化疗对比铂类化疗联合或不联合贝伐珠单抗用于治疗老年人晚期非小细胞肺癌的一线治疗。
Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD015495. doi: 10.1002/14651858.CD015495.
5
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.西妥昔单抗联合化疗与单纯化疗用于初治晚期非小细胞肺癌的疗效比较
Cochrane Database Syst Rev. 2014 Nov 17;2014(11):CD009948. doi: 10.1002/14651858.CD009948.pub2.
6
Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.不可切除的 III 期非小细胞肺癌患者同步低剂量顺铂与胸部放疗：一项特别参照血红蛋白水平作为预后参数的 II 期试验
J Cancer Res Clin Oncol. 2005 Apr;131(4):261-9. doi: 10.1007/s00432-004-0633-0. Epub 2004 Dec 23.
7
Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer.循环中的MACC1作为非小细胞肺癌的一种新型诊断和预后生物标志物。
J Cancer Res Clin Oncol. 2015 Aug;141(8):1353-61. doi: 10.1007/s00432-014-1903-0. Epub 2014 Dec 28.
8
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.早期非小细胞肺癌切除术后的辅助化疗
Cochrane Database Syst Rev. 2015 Mar 2;2015(3):CD011430. doi: 10.1002/14651858.CD011430.
9
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.一线化疗治疗成人局部晚期或转移性非小细胞肺癌的临床效果和成本效益：系统评价和经济评估。
Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310.
10
The Prognostic Value of Nutritional and Immune Indices for Stage IB Non-Small Cell Lung Cancer Patients: Insights From a Retrospective Cohort Study.营养和免疫指标对ⅠB期非小细胞肺癌患者的预后价值：一项回顾性队列研究的见解
Cancer Med. 2025 Aug;14(15):e71089. doi: 10.1002/cam4.71089.

本文引用的文献

1
Silencing of induces epithelial‑to‑mesenchymal transition in lung cancer cell lines with different effects on proliferation and clonogenic growth.[基因名称]的沉默在肺癌细胞系中诱导上皮-间质转化，对增殖和克隆生长有不同影响。 （注：原文中“Silencing of ”后面缺少具体基因名称，这里翻译时补充了“[基因名称]”）
Oncol Lett. 2023 Jul 25;26(3):391. doi: 10.3892/ol.2023.13977. eCollection 2023 Sep.
2
Analyses of rare predisposing variants of lung cancer in 6,004 whole genomes in Chinese.中国 6004 例全基因组中肺癌罕见易感变异体的分析。
Cancer Cell. 2022 Oct 10;40(10):1223-1239.e6. doi: 10.1016/j.ccell.2022.08.013. Epub 2022 Sep 15.
3
Expanding Horizons for Treatment of Early-Stage Lung Cancer.拓展早期肺癌治疗的视野
N Engl J Med. 2022 May 26;386(21):2050-2051. doi: 10.1056/NEJMe2203330. Epub 2022 Apr 11.
4
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology.2022 年非小细胞肺癌：肿瘤学全科医生综述。
Curr Oncol. 2022 Mar 9;29(3):1828-1839. doi: 10.3390/curroncol29030150.
5
Grainyhead-like (Grhl) Target Genes in Development and Cancer.粒头样 (Grhl) 靶基因在发育和癌症中的作用。
Int J Mol Sci. 2022 Mar 1;23(5):2735. doi: 10.3390/ijms23052735.
6
Comparison of Ga-FAPI and F-FDG PET/CT in the Evaluation of Advanced Lung Cancer.Ga-FAPI 与 F-FDG PET/CT 在晚期肺癌评估中的比较。
Radiology. 2022 Apr;303(1):191-199. doi: 10.1148/radiol.211424. Epub 2022 Jan 4.
7
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.早期和局部晚期非小细胞肺癌：聚焦诊断、分期、全身及局部治疗的ESMO临床实践指南更新
Ann Oncol. 2021 Dec;32(12):1637-1642. doi: 10.1016/j.annonc.2021.08.1994. Epub 2021 Sep 1.
8
Lung cancer.肺癌
Nature. 2020 Nov;587(7834):S7. doi: 10.1038/d41586-020-03152-0.
9
Update 2020: Management of Non-Small Cell Lung Cancer.更新于 2020 年：非小细胞肺癌的治疗。
Lung. 2020 Dec;198(6):897-907. doi: 10.1007/s00408-020-00407-5. Epub 2020 Nov 11.
10
Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival.深度学习模型在非小细胞肺癌生存预测中的建立与验证。
JAMA Netw Open. 2020 Jun 1;3(6):e205842. doi: 10.1001/jamanetworkopen.2020.5842.

放疗和化疗后血液 GRHL2 对非小细胞肺癌患者的预后价值。

Prognostic value of blood GRHL2 in patients with non-small-cell lung cancer after radiotherapy and chemotherapy.

机构信息

Changzhou Cancer Hospital, Changzhou City, Jiangsu Province, 213000, P.R. China.

出版信息

Biomark Med. 2024;18(13-14):611-617. doi: 10.1080/17520363.2024.2366161. Epub 2024 Jul 29.

DOI:10.1080/17520363.2024.2366161
PMID:39073846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11370899/
Abstract

We aimed to investigate the predictive value of the Grainyhead-like 2 (GRHL2) expression from circulating blood for recurrence, metastasis and overall death on patients with non-small-cell lung cancer (NSCLC). We collected blood samples from 122 patients who were admitted to our hospital for NSCLC. Multivariable Cox proportional-hazards analysis in adjusted Model II showed that compared with GRHL2-negative expression, positive expression in patients with NSCLC was associated with increased death risk (HR = 7.0, 95% CI: 2.1-20.9,  = 0.03) and risk for composite end point (HR = 8.2, 95% CI: 4.0-27.1, <0.01). This study supported that elevated circulating GRHL2 expression might be considered as a candidate prognostic biomarker for poor prognosis among these NSCLC patients.

摘要

我们旨在探讨来自循环血液的 Grainyhead-like 2 (GRHL2) 表达对非小细胞肺癌 (NSCLC) 患者复发、转移和总死亡的预测价值。我们收集了 122 名因 NSCLC 住院的患者的血液样本。调整后的模型 II 多变量 Cox 比例风险分析显示，与 GRHL2 阴性表达相比，NSCLC 患者的阳性表达与死亡风险增加（HR=7.0，95%CI：2.1-20.9，=0.03）和复合终点风险（HR=8.2，95%CI：4.0-27.1，<0.01）相关。这项研究支持循环 GRHL2 表达升高可能被认为是这些 NSCLC 患者预后不良的候选预后生物标志物。